Particle.news
Download on the App Store
4 ARTICLES
·
last wk.

Nonhormonal Male Pill YCT-529 Clears First Human Safety Trial

Backed by favorable safety data with a two-to-three-day half-life, YCT-529 is now entering efficacy studies to evaluate its impact on sperm production.

Image
Image
Image
First Ever Nonhormonal Birth Control for Males Found Safe, Effective in Human Trial

Overview

  • In a phase 1 trial of 16 vasectomized men, YCT-529 was well tolerated at doses up to 180 mg with no drug-related adverse effects observed.
  • The pill targets a vitamin A metabolite receptor in the testes to halt the gene-expression processes required for sperm development.
  • Pharmacokinetic analysis showed a two-to-three-day blood half-life, indicating potential for once-daily dosing if effectiveness is demonstrated.
  • Safety results published July 22 in Communications Medicine represent the first human data on a reversible, nonhormonal male contraceptive.
  • YourChoice Therapeutics has initiated follow-up trials to measure sperm suppression and prepare for larger phase 2 and phase 3 studies.